You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

BEXSERO dosing and administration

Go to Close Top

Recommended dosing schedule for BEXSERO 1

The table shows the Recommended dosing schedule for BEXSERO. For a detailed description of the table, please contact GSK customer service at 1-800-387-7374.

* The need for, and timing of further doses has not yet been determined.

BEXSERO should be given by deep intramuscular injection, preferably in the anterolateral aspect of the thigh in infants or in the deltoid muscle region of the upper arm in older subjects. The vaccine must not be mixed with other vaccines or medicinal products in the same syringe.

When given concomitantly with other vaccines, BEXSERO should be administered at a different injection site. BEXSERO must not be mixed with other medicinal products or other vaccines in the same syringe.

Sufficient data are not available on the safety and effectiveness of using BEXSERO and other meningococcal group B vaccines interchangeably to complete the vaccination series. Therefore, it is recommended that subjects who receive a first dose of BEXSERO complete the vaccination course with BEXSERO.

Your patients can visit BEXSERO.ca for a handy dose planner. They can also sign up for dose reminders via text or email.

For children, adolescents and adults aged 2 through 25 years, the second dose should be administered not less than one month after the first dose; a booster should be considered in individuals at continued risk of exposure to meningococcal disease, based on guideline recommendations.

BEXSERO provides flexible dosing options intended to fit routine vaccination visits and can be co-administered with other vaccines 1

BEXSERO can be given concomitantly with any of the following vaccine antigens (either as monovalent or as combination vaccines):

  • diphtheria
  • tetanus
  • acellular pertussis
  • H. influenzae type b
  • inactivated poliomyelitis
  • hepatitis B
  • heptavalent pneumococcal conjugate
  • measles
  • mumps
  • rubella
  • varicella
  • meningococcal groups A, C, W, Y conjugate

As higher percentages of subjects reported systemic reactions, including fever, change in eating habits, tenderness at the injection site and irritability, following BEXSERO given concomitantly with routine vaccines than after BEXSERO alone, separate vaccinations can be considered when possible. Prophylactic use of acetaminophen reduces the incidence and severity of fever without affecting the immunogenicity of either BEXSERO or most antigens of routine vaccines. The effect of antipyretics other than acetaminophen on the immune response has not been studied.

Concomitant administration of BEXSERO with vaccines other than those mentioned above has not been studied.

BEXSERO should be given by deep intramuscular injection, preferably in the anterolateral aspect of the thigh in infants or in the deltoid muscle region of the upper arm in older subjects.

When given concomitantly with other vaccines, BEXSERO should be administered at a different injection site. BEXSERO must not be mixed with other medicinal products or other vaccines in the same syringe.

Reference:

  1. BEXSERO Product Monograph. June 12, 2020.

This page is for Healthcare Professionals only. If you are not a Healthcare Professional, please visit Bexsero.ca.